首页> 外国专利> SYNTHESIS AND IN SILICO STUDIES OF NOVEL ANTI-SARS-COV SULFONAMIDES AS POTENTIAL INHIBITORS AGAINST COVID-19 PROTEIN TARGET: SARS-COV-2 MAIN PROTEASE (M PRO )

SYNTHESIS AND IN SILICO STUDIES OF NOVEL ANTI-SARS-COV SULFONAMIDES AS POTENTIAL INHIBITORS AGAINST COVID-19 PROTEIN TARGET: SARS-COV-2 MAIN PROTEASE (M PRO )

机译:新型抗SAR2019冠状病毒疾病的合成及在SoC-SV COV抑制剂中的应用

摘要

A cluster of pneumonia cases and COVID-19 pandemic that started in Wuhan, China, was caused by novel beta coronavirus, the 2019 novel coronavirus (2019-nCoV). This has led to many number of deaths and many were infected worldwide owing to the absence of effective therapies against coronavirus 2 of the severe acute respiratory syndrome (SARS-CoV-2). Viral maturation requires the activity of the main viral protease (Mpro) and thereby, inhibition stops the advancement of the disease. The current invention delivers a potential anti-viral drug candidates docked against COVID-19 protein targets: SARS-CoV-2 main protease, drug-likeness, efficacy, molecular docking, physicochemical and pharmacokinetic studies of novel synthesized sulfonamide analogues. Physicochemical and pharmacokinetic properties have been evaluated on the basis of certain parameters like Lipinski rule of 5 (RO5 rule) and ADMET (absorption, distribution, metabolism, excretion and toxicity). All the synthesized compounds follow Lipinski rule of five (RO5 rule) and the compounds followed the range of rotational bonds, hydrogen bond acceptors (HBA), hydrogen bond donors (HBD), topological surface area (TPSA), number of violations, etc. All these compounds shown good pharmacokinetic properties, zero renal OCT2 substrate toxicity and negligible toxicity values. BOILED-egg model was carried out for evaluating the gastrointestinal absorption and brain penetration effect. Compounds 3b and 3d comes under white region of egg and exhibited good gastrointestinal absorption, whereas, 3a, 3c, 3e and 3f compounds fall under yellow region (yolk) of egg which showed good brain penetration effect. All novel sulfonamide analogues including commercially available anti-COVID-19 drugs, Hydroxychloquine and Umifenovir docked with COVID-19 protein targets, i.e., PDB: 6VWW & 6Y2E.Compound 3c when docked with PDB: 6VWW shown maximum energy of -22.06 kcal/mol with two hydrogen binding interactions which are better than marketed drugs. Similarly, compound 3a exhibited highest energy of -14.00 kcal/mol.
机译:新型冠状病毒(2019 2019冠状病毒疾病)是由中国武汉市开始的一种肺炎病例和COVID-19流行病。由于缺乏针对严重急性呼吸综合征(SARS-CoV-2)冠状病毒2的有效疗法,这导致了许多人死亡,许多人在世界范围内受到感染。病毒成熟需要主要病毒蛋白酶(Mpro)的活性,因此,抑制阻止疾病的进展。本发明提供了2019冠状病毒疾病的候选候选抗病毒药物:SARS COV-2蛋白酶、药物相似性、功效、分子对接、物理化学和药代动力学研究新合成的磺酰胺类似物。理化和药代动力学特性是根据某些参数进行评估的,如Lipinski规则5(RO5规则)和ADMET(吸收、分布、代谢、排泄和毒性)。所有合成的化合物都遵循Lipinski五规则(RO5规则),并且化合物遵循旋转键范围、氢键受体(HBA)、氢键供体(HBD)、拓扑表面积(TPSA)、违例数等。所有这些化合物都显示出良好的药代动力学特性、零肾OCT2底物毒性和可忽略的毒性值。采用煮沸鸡蛋模型评价胃肠道吸收和脑渗透效应。化合物3b和3d位于鸡蛋的白色区域,表现出良好的胃肠道吸收,而化合物3a、3c、3e和3f位于鸡蛋的黄色区域(蛋黄),表现出良好的脑渗透效果。所有新的磺酰胺类似物,包括市售的抗COVID-19药物,羟喹喹和乌米诺韦,与COVID-19蛋白靶标对接,即PDB:6VWW和6Y2E。当化合物3c与PDB对接时:6VWW显示出-22.06 kcal/mol的最大能量,具有两种氢键相互作用,这比上市药物更好。类似地,化合物3a的最高能量为-14.00 kcal/mol。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号